The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

Journal of Virology

Volumn 74, Issue 8, 2000, Pages 3579-3585

  Götte, Matthias ^a   Arion, Dominique ^a   Parniak, Michael A ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; LAMIVUDINE; MUTANT PROTEIN; NUCLEOSIDE TRIPHOSPHATE; PYROPHOSPHATE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTI-HIV AGENTS; BASE SEQUENCE; DIPHOSPHATES; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; TEMPLATES, GENETIC; ZIDOVUDINE;

EID: 0142100752     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.8.3579-3585.2000     Document Type: Article

References (40)

1. Argos, P. 1988. A sequence motif in many polymerases. Nucleic Acids Res. 16:9909-9916.
2. Arion, D., N. Kausshik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908-15917.
3. Back, N. K. T., M. Nijhuis, W. Keulen, C. A. B. Boucher, B. B. O. Essnik, A. B. P. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
4. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
5. Canard, B., S. R. Sarfati, and C. C. Richardson. 1998. Enhanced binding of azidothymidine-resiscant human immunodeficiency virus 1 reverse transcriptase to the 3′-azido-3′-deoxythymidine 5′-mono-phosphate-terminated primer. J. Biol. Chem. 273:14596-14604.
6. Carroll, S. S., J. Geib, D. B. Olsen, M. Stahlhut, J. A. Shafer, and L. C. Kuo. 1994. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry 33:2113-2120.
7. Feng, J. Y., and K. S. Anderson. 1999. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 38:55-63.
8. Feng, J. Y., and K. S. Anderson. 1999. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 38:9440-9448.
9. Finzi, D., J. Blankson, J. D. Siliciano, J. B. Margolick, K. Chadwick, T. Pierson, K. Smith, J. Lisziewicz, F. Lori, C. Flexner, T. C. Quinn, R. E. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, and R. F. Siliciano. 1997. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
10. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
11. Götte, M., G. Maier, A. Mochi Onori, L. Cellai, M. A. Wainberg, and H. Heumann. 1999. Temporal coordination between initiation of HIV (+)-strand DNA synthesis and primer removal. J. Biol. Chem. 274:11159-11169.
12. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
13. Günthard, H. F., J. K. Wong, C. C. Ignacio, J. C. Guatelli, N. L. Riggs, D. V. Havlir, and D. D. Richman. 1998. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72:2422-2428.
14. Hsieh, J.-C., S. Zinnen, and P. Modrich. 1993. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 268:24607-24613.
15. Hsu, M., P. Inouye, L. Rezende, N. Richard, Z. Li, V. R. Prasad, and M. A. Wainberg. 1997. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant that wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res. 25:4532-4536.
16. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
17. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., X. Lu, C. Tantillo. R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.
18. Kerr, S. G., and K. S. Anderson. 1997. Pre-steady-state kinetic characterization of wild type and 3′-azido-3′deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry 36:14064-14070.
19. Krebs, R., U. Immendörfer, S. H. Thrall, B. M. Wöhrl, and R. S. Goody. 1997. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucloside inhibitors zidovudine and 3-TC. Biochemistry 36:10292-10300.
20. Lacey, S. F., J. E. Reardon, E. S. Furfine, T. A. Kunkel, K. Bebenek, K. A. Eckert, S. D. Kemp, and B. A. Larder. 1992. Chemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′deoxythymidine. J. Biol. Chem. 267:15789-15794.
21. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
22. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
23. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:969-699.
24. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95:13471-13476.
25. Meyer, P. R., S. E. Matsuura, A. Mohsin Mian, A. G. So, and W. A. Scott. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4:35-43.
26. Oude Essnik, B. B., N. K. Back, and B. Berkhout. 1997. Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Res. 25:3212-3217.
27. Pandey, V., N. Kaushik, N. Rege, S. G. Sarafianos, P. N. S. Yadav, and M. J. Modak. 1996. Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 35:2168-2179.
28. Quan, Y., Z. Gu, X. Li, Z. Li, C. D. Morrow, and M. A. Wainberg. 1996. Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J. Virol. 70:5642-5645.
29. Quan, Y., P. Inouye, L. Rong, M. Götte, and M. A. Wainberg. 1998. Dominance of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing. J. Biol. Chem. 273:21918-21925.
30. Quan, Y., Z. Gu, X. C. Liang, M. A. Parniak, and M. A. Wainberg. 1998. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. J. Mol. Biol. 227:237-247.
31. Rezende, L. F., W. C. Drosopoulos, and V. R. Prasad. 1998. The influence of 3TC resistance mutation M1841 on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Nucleic Acids Res. 26:3066-3072.
32. Rooke, R., M. Tremblay, H. Soudeyns, L. DeStephano, X.-J. Yao, M. Fanning, J. S. G. Montaner, M. O'Shaugnessy, K. Gelmon, C. Tsoukas, J. Ruedy, and M. A. Wainberg. 1989. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine (AZT) therapy. AIDS 3:411-415.
33. Sarafianos, S. G., K. Das, A. D. Clark, Jr., J. Ding, P. L. Boyer, S. H. Hughes, and E. Arnold. 1999. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. USA 96:10027-10032.
34. Sarafianos, S. G., K. Das, J. Ding, P. L. Boyer, S. H. Hughes, and E. Arnold. 1999. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem. Biol. 6:137-146.
35. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency virus resistant to oxathiolanecytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
36. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Shipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
37. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
38. Wainberg, M. A. 1999. HIV resistance to antagonists of viral reverse transcriptase, p. 223-249. In A. G. Dalgleish and R. A. Weiss (ed.), HIV and the new viruses. Academic Press, Inc., London, United Kingdom.
39. Wainberg, M. A., W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. A. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, and V. R. Prasad. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 217:1282-1285.
40. Wong, J. K., M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.